Confirming Ipsen's biopharmaceuticals profile

Jefferies - 4th Annual Healthcare Conference
New York, June 10th & 11th 2010

Jacques-Pierre Moreau – Chief Scientific Advisor
David Schilansky – Vice President Finance
Pierre Kemula – Investor Relations Officer

Disclaimer

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

Quick overview of some fundamentals

The fundamentals : restoring physiological balance



Therapeutic corollary : restore physiological levels, no more, no less

The fundamentals : the hormonal pathway and cascade



Ipsen has a specific knowledge of pituitary disorders

The fundamentals: Ipsen's specialty care vs. primary care businesses

Primary care | **Specialty care**

- Sales efforts
- Number of patients required in trials
- Production volumes
- Price pressure
- Unmet medical needs
- Investment in Innovation

\+ - - +

Ipsen in short

Ipsen today : a global biotech specialty pharma…

	SPECIALTY CARE A global business to **GROW**	PRIMARY CARE **OPTIMISE** presence	
24%	**ONCOLOGY** Decapeptyl®	GI	18%
20%	**ENDOCRINOLOGY** Somatuline®, Nutropin®, Increlex®	Cognitive disorders	11%
16%	**NEUROLOGY** Dysport® , Apokyn®	Cardiovascular	7%
-	HEMATOLOGY **INSPIRATION** partnership	Others*	4%

Over €1 billion in total sales in 2009

A unique innovation driven and differentiated R&D capability
R&D expense ~20% of sales

A transactional model

* Other Pharmaceutical products (Primary Care) and Drug Related Sales

IPSEN
Innovation for patient care

…with leading positions internationally…



2008 rounded Market shares, except for Somatuline® in the US: 4Q09
Market shares are for (i) Dysport® in medical indications (ii) Decapeptyl in prostate cancer (China gynecology only) and (iii) Somatuline in Acromegaly only.
* In the US, market share in patients treated by endocrinologists and in pituitary centers
Sources: IMS, Insight Health/ODV, Ipsen estimates, Strategix

IPSEN
Innovation for patient care

…continuously outgrowing its main competitors

2009 sales of Dysport®
+18.0% y-o-y at constant currency

2009 sales of Somatuline®
+18.2% y-o-y at constant currency

2009 sales of NutropinAq®
+26.5% y-o-y at constant currency

Strong and continued specialty care dynamics
+13.9% y-o-y at constant currency

Today, a reinforced profile…



Confirming Ipsen's biotech specialty care profile

Truly Differentiated R&D Capabilities

Example 1 : Somatuline® Depot

	Sandostatin LAR®	Somatuline® Autogel®
Administration	2.0 ml Intramuscular	0.3 ml – 0.5 ml Subcutaneous
Presentation	Powder vial + solvent filled syringe + 2 needles	Pre-filled syringe
Injection technique	10 steps needed to reconstitute	Ready to use Self administration*

*For what reasons would you prescribe Somatuline® Depot to your acromegaly patients?***



Somatuline® Depot: A self administration syringe, an improved quality of life

** In selected countries*

*** Study Sample: A total of 50 US endocrinologists completed a 30-minute online questionnaire between April 4 - 17, 2008*
25 High Volume Endocrinologists: Endocrinologists who see 11 or more acromegaly patients in a year
25 Low Volume Endocrinologists: Endocrinologists who see between 5-10 acromegaly patients in a year

Example 2 : a unique technology convergence, taspoglutide

	Liraglutide Flex Pen	Byetta LAR*	Taspoglutide PFS**
Administration	**Daily**	**Weekly**	**Weekly**
Device	**Multiple use** **Needle: 32 gauge**	**Single-use**, **syringe & vial** **Needle : 23 gauge**	**Single-use**, **staked-in needle** **Needle: 29 gauge**
Injection technique	1.Attach needle 2.Prime pen 3.Set dose 4.Inject	1.Re-constitute 2.Draw into syringe 3.Inject	1.Remove cap 2.Inject

Taspoglutide : 50 to 300 µl of highly concentrated aqueous solution devoid of excipient

** Long-acting release*
*** Pre-filled syringe*

Selected potential future growth drivers

Snapshot

Internationalization Fast growing presence in Russia, China, Brazil and emerging markets **Entering the US**	**Hematology** Capitalizing on OBI-1 to build a unique portfolio of compounds in hemophilia
Life cycle management Somatuline IGF-I+GH coadministration Decapeptyl 6-month	**Rich R&D pipeline** BN83495 BIM 23A760 …

Growth and globalization beyond G5…

Entering the world's largest pharma market with 4 specialty care products

Dysport®
Somatuline®
Increlex®
Apokyn®

A diversified portfolio in the fastest growing Eastern European pharma market

Dysport®
Decapeptyl®
Tanakan®
Smecta®



Dynamic specialty care presence in the largest South American pharma market

Dysport®

Partnership with Galderma for aesthetics

Longstanding and strong positions in one of the world's largest pharma market

Decapeptyl®
Smecta®

…translating into rapid expansion



Evolution of Group sales outside the G5

Capitalizing on OBI-1 with the Inspiration partnership…



All blood-related disorders

All coagulation disorders
Market Size $19.5 billion

Ipsen's and Inspiration's core strategic focus

Lack of coagulation blood factor
Market Size $7.5 billion

Inhibitor (antibodies) to replacement coagulation factor

Inhibitor (antibodies) to natural coagulation factor

Market Size $1.5 billion (all Inhibitor)

….to build a unique franchise covering all needs in hemophilia…

	PRE CLIN	PHASE I	PHASE II	PHASE III	INSPIRATION EXPECTED FILING DATES
IB1001 (FIX)	●	●	●	●	2011
OBI-1 (pFVIII)	●	●	●	●	2012 (acquired) 2013 (congenital)
FVIIa	●				2014
FVIII	●				2015

A recombinant product in each segment of the hemophilia market

… with no equivalent currently on the market

	Inspiration	Wyeth	Baxter	CSL Behring	Bayer	Novo Nordisk	Biogen Idec and Biovitrum
FIX	Phase III	BeneFIX	Phase I	Mononine plasma derived	-	Phase I	Phase III (fusion protein)
OBI-1	Phase III	-	-	-	-	-	-
FVIIa	Preclinical	Preclinical	-	Preclinical	Phase I	Novoseven	-
FVIII	Preclinical	Refacto Xyntha	Advate Recombinate	Helixate	Kogenate	Phase III	-

Inspiration will be the company with the most comprehensive portfolio of hemophilia solutions

Marketed products

A progressive path of control of Inspiration



Initial equity stake: $85 m + OBI-1 upfront: $50 m + 27.5% royalty rate on OBI-1

Total development funding of $174m in exchange for convertible bonds maturing the later of 7 years or the end of the call exercise period

Call at market value exercisable on triggering events expiring at the latest in 2019

** O/W 20% of outstanding shares*

Somatuline® offers significant life cycle growth opportunities



Significant scope for expansion

Redefining the treatment of short stature



COMBO in IGFD

- MS316: Ph II dose titration study recruitment completed in Q2 '09
  - Interim results announced in September 09
    - Complete results available in H2 '10

Rationale for Sulfatase inhibitor development

Inhibition of Androstenediol synthesis from DHEA-S



After encouraging phase I results, BN83495 is now in phase II clinical trial

BN83495 : Moving forward in the development stages

Phase I — **Phase II**

ENDOMETRIAL CANCER

Phase II initiated - 80 patients to be treated

First patient dosed on November 25, 2009

METASTATIC BREAST CANCER (ER)

Phase I/II on going – 50 patients

Preliminary results presented at the SABCS (dec. 09).
OBD determined: 40 mg 1 per day

Additional 15 patients included to study target enzyme (STS) inhibition in cancerous cell

PROSTATE CANCER

CASTRATE RESISTANT

Phase I/II on going

Dose escalation

Progress and Outlook

2009: major initiatives, in a rigorous execution of the Group's strategy

Grow and Globalize Ipsen's *specialty care* business

4 products in the US, 3 global	6 products in launch phase	Decapeptyl® 6M approved in Europe	Rich phase II/ III programmes	Out licensing of none core compounds

+

Optimize Ipsen's *primary care* business

Rich deal with Menarini on Adenuric®	Promising headline results for taspoglutide (Roche)	BLI-800 (Braintree)

All key milestones delivered in 2009

Phase I	Phase II/ III	Regulatory	Launch
			Adenuric® Partnership(s) and launches ✓
	IGF-I+GH co-admin Phase II interim results ✓	Decapeptyl® 6 Months Approval ✓	Primary care products In-licensing deal(s) ✓
	BIM-23A760 Phase II initiation ✓	Azzalure® Approval in Europe ✓	Azzalure® Launch by Galderma ✓
BN-83495 Phase I results Breast cancer ✓	BN-83495 Phase II initiation Endometrial cancer ✓	Dysport® (aesthetics) FDA approval ✓	Dysport® (aesthetics) Launch by Medicis ✓
BIM-28131 (Ghrelin) Phase I initiation	Somatuline® Depot US NET Phase III initiation ✓	Dysport® (therapeutic) FDA approval ✓	Dysport® (therapeutic) Launch ✓

All financial objectives have been met in 2009

	Financial objectives Q1-09	*Bayer Settlement* → Financial objectives Q3-09	2009 performance
Drug sales	**+ 7.0 – 9.0%**		**+ 7.6%** ✓
Other Revenues	**Around €45m**	**Approx. €80m**	**€79.6 millions** ✓
Adjusted operating margin[1]	**14.0%**	**17.0 – 17.5%**	**17.8%** ✓
Normative Tax rate	**18.0 - 20.0%**		**6.3%** ✓

NOTE 1: in percentage of sales, prior to any accounting implications in connection with the purchase accounting of its acquisitions in North America

IPSEN Innovation for patient care

A rich newsflow in 2010, already initiated

Clinical development		Regulatory / Launch
		Somatuline® Depot US filing Extended Dosing Interval
	Taspoglutide Phase III results Diabetes	Somatuline® Autogel® Launch in Russia Acromegaly + NET
BIM-28131 (Ghrelin) Partnered ✓	OBI-1 Phase III initiation	Decapeptyl® 3 Months Launch in China Prostate cancer ✓
IGF-I+GH co-admin Phase II Data available	Dysport® Phase III initiation (US) Adult+children lower limb spasticity	Decapeptyl® 6 Months Launch in Europe ✓
BIM 23A760 Phase II initiation (WW) Neuro Endocrine Tumors (NET) ✓	Tanakan® Phase III data available (GuidAge®)	Adenuric® Launch ✓

Continuous and rigorous execution of Ipsen's strategy
➔ Specialty care growth & globalization, and increase in R&D efficacy
➔ Primary care contribution optimization

IPSEN Innovation for patient care

All financial objectives for 2010

	Financial objectives 2010	
Specialist Care - Drug sales	Close to double digit growth	3% to 5% growth*
Primary Care - Drug sales	(5)% to (7)% decrease*	
Other Revenues	Close to 50€ million	
Recurring Adjusted operating margin**	Approx. 15% growth*	
Recurring Adjusted EPS**	Relative stability with 2009	

The above objectives are set at constant currency
2010 objective excludes any potential non recurring items

** Margins expressed in % of sales*
*** Prior to any accounting implications in connection with the purchase accounting of its acquisitions in North America and non recurring elements*

APPENDIX

R&D Pipeline

A rich endocrinology pipeline



A promising Oncology pipeline



** Option to in-license*

Taspoglutide : Potential Best-in-class profile

Reported

T-emerge programme :

- –**T-E 1:** Taspoglutide vs. placebo
- –**T-E 2:** Taspoglutide QW vs. exenatide BID
- –**T-E 4:** Taspoglutide vs. sitagliptin vs. placebo
- –**T-E 5:** Taspoglutide vs. insulin glargine
- –**T-E 7:** Taspoglutide vs. placebo (metformin failures [high BMI])

Toxicology data :

- –**Results of carcinogenicity studies support the ongoing clinical development of taspoglutide;**
- –**These results apply to mice as well**

Filling during 2011

To be reported

T-emerge programme :

- –**T-E 3:** Taspoglutide vs. placebo (pioglitazone + metformin failures)
- –**T-E 6:** Taspoglutide vs. pioglitazone

Full body of data (efficacy, safety, potential side effects) :

- –**American Diabetes Association, June 26- 29 2010**

APPENDIX

Financial objectives

IPSEN
Innovation for patient care

IPSEN
Innovation for patient care

Top line objectives for 2010

Close to double digit Reported Speciality Care drug sales

Double digit in-market Speciality Care drug sales

+	Dynamic international markets	Launch of Decapeptyl 6 month in Europe	Continued expansion of its US platform
-	Slower growth in Eastern Europe	Transition of aesthetic activities to partners	Changing US market conditions

Primary Care drug sales to decrease by (5) to (7)% year-on-year

+	International markets from increasing to c.50% from 45% of total Primary Care drug sales
-	French primary care environment

Group Drug Sales growth between 3.0 and 5.0% year-on-year

Other Revenues close to €50 million depending on the performance of the Group's partners

The above objectives are set at constant currency

Profitability objectives for 2010

Recurring adjusted operating result

Fully diluted adjusted EPS



The Group targets an increase of its adjusted operating result and a relative stability of its consolidated income in a context of a significantly expanded R&D footprint

2010 objective excludes any potential non recurring items

In the longer term…

July 2008 | **2009** | **2010** | **2011** | **Longer term**

High US double-digit growth
coupled with significant profitability improvements

Continued US penetration
with 4 marketed specialty care products,
of which Dysport® just recently launched

Financial crisis
profound changes in global equilibrium
and macroeconomic conditions

Increased primary care competitive environment

The Group today cannot confirm its 2011 and 2012 perspectives, or at least their timeframe

APPENDIX

Full year 2009 detailed financial performance

Top line evolution

Sales by therapeutic area



Sales by region



Other revenues evolution



Total revenues evolution



Evolution of main P&L expenses

COGS (% of sales)



Research & Development



Sales & Marketing



G&A



NOTE 1 : Adjusted for the impacts related to purchase price accounting in connection with the Group's acquisitions
NOTE 2: in orange: outside North America

P&L – 2009 operating result and margin



Margins expressed in % of sales

IPSEN
Innovation for patient care

P&L – below EBIT

Financial result (€m)



Effective tax rate



Income from Associates (€m)



Consolidated result (€m - group share)



NOTE 1 : Adjusted for the impacts related to purchase price accounting in connection with the Group's acquisitions

IPSEN
Innovation for patient care

Balance Sheet evolution

(€m)

Assets

	31 Dec 08	31 Dec 09
Goodwill	290.8	290.2
Property. plans & equipments	237.9	251.8
Intangible assets	232.9	237.0
Other non-current assets	112.9	145.5
Total non-current assets	**874.5**	**924.5**
Total current assets	**688.6**	**652.4**
Incl. cash and cash equivalents	239.6	218.6
Discontinued operations	1.3	0.0
Total assets	**1,564.4**	**1,576.9**
Net Cash	**66.2**	**185.6**

Liabilities

	31 Dec 08	31 Dec 09
Equity	885.0	982.6
Minority interests	1.6	1.7
Total equity	**886.6**	**984.3**
Long-term financial debts	162.7	12.2
Other non-current liabilities	194.2	270.3
Short-term debts	10.6	21.4
Other current liabilities	305.4	286.7
Discontinued operations	4.9	2.0
Total Liabilities	**1,564.4**	**1,576.9**

Significant increase of partnership related deferred revenues

Total Milestones cashed-in but not yet recognised as revenues



Main milestones cashed-in in 2009

May
Medicis: $75m upon approval of Dysport®

March - September
Galderma: €20m upon approval and launches of Azzalure®

October
Menarini: €20m upon signing of partnership for Adenuric®

Cash flow statement

€m	31 Dec 08	31 Dec 09
Cash Flow before change in working capital	**196.3**	**192.7**
- Increase/ Decrease in working capital	7.4	64.9
Net cash flow generated by operating activities	**203.7**	**257.6**
Investment in tangible assets	(61.4)	(40.3)
Investment in Intangible assets	(33.8)	(24.7)
Others	(190.3)	(6.3)
Net cash flow used in investing activities	**(285.5)**	**(71.3)**
Net change in borrowings	141.0	(151.3)
Dividends paid	(55.0)	(58.0)
Others	(7.0)	(5.4)
Net cash flow used in financing activities	**79.0**	**(214.8)**
Discontinued operations	0.7	(1.0)
Change in cash and cash equivalent	**(2.1)**	**(29.5)**
Impact of exchange rate fluctuations	(1.5)	(2.4)
Closing cash & cash equivalents	**237.3**	**205.4**
Closing Net Cash	**66.2**	**185.6**

- Net increase in deferred revenues from partnerships: +€73.9m
- Reimbursement of syndicated credit facility €(150) m

Appendix

Focus on the performance of Ipsen's US franchise

IPSEN
Innovation for patient care

IPSEN
Innovation for patient care

US platform integrated and fully operational

Strong and experienced management team :
New President and General Manager (May 2009)
New leadership team in key positions (Clinical & Medical Affairs, legal, HR, …)

Fully operational managed care organisation (22 FTEs), including Payer Relation Management

Customer support programs in place, essential to US success
Implementing PACE program (Patient assistance, Access to services, Continuity of care, Education) for each product

Full clinical development and regulatory capability in the US
allowing for global developments of key programs

4 products now marketed, promoted by a Sales Force of 75

Somatuline® Depot market in the US

US Market structure – 15 000 to 18 000 patients



- **Good penetration of Somatuline® Depot**
  - **20% share**[2] of endocrinologists prescriptions
  - **40% market share**[2] in pituitary centers
- **Significant pool of untreated patients**
- **Relatively low compliance compared to Europe**

Drive Somatuline® Depot as first line recommendation in Pituitary centers and Endocrinologists

Drive Somatuline® Depot access and persistence

NOTE 1 : Prevalence of 60 per million
NOTE 2 : Q409 market share established by Wolters Kluwer

Snapshot on Increlex® and Dysport®

Increlex®

Established treatment option:
Number of SMN[1]s up more than 31% year-on year

Establishment of specialized Reimbursement & Endocrinologist dedicated support teams

+40% increase in sales in 2009

30% decrease in patient drop out rate in 2009

Dysport®

Great interest from commercial payors Dysport® enjoys an 85% coverage rate (commercial) and a 100% coverage rate (government)	**Fully integrated in US reimbursement system** Dysport®'s J-Code secured for March 2010
Excellent brand awareness Dysport® known by more than 80% of target prescribing population at launch	**Higher-than-expected success of sampling campaign** Dysport® requested by twice as many neurologists as originally anticipated

NOTE 1: Statement of Medical Necessity

A change in US context

Difficult economic situation impacting finances of patients

Increased pressure from commercial payers with tougher reimbursement criteria

Enforcement of strict compliance environment

Appendix

Partnership with Inspiration in Hematology

Despite improved life expectancy and treatment of patients with hemophilia…

Improved life expectancy



SOURCE: Larsson SA, et al. Br J Haematol 1985;59:593–602

Improved treatments



Survival in men in the UK with hemophilia who were not infected with HIV and in the general male population of the UK in 1999
SOURCE: Darby SC. et al. Blood 2007;110:815–825

…FVIII & FIX market are still underserved globally…

Factor VIII



Factor IX



Low penetration

- **70% of hemophilia patients worldwide do not have access to factors**

Long term growth prospects

- 4% to 10% CAGR until 2020
- Driven by prophylaxis in developed world
- Driven by more patients treated in RoW
- 90% recombinant in developed world
- 40% and growing in RoW

Most important unmet need today: Enable access to treatment to more patients

Sources: MRB, Market intelligence
NOTE 1 - IU: International Units

…resulting in high unmet medical needs in all segment of hemophilia



[1] Rare factor deficiencies: FV, FVII, etc…
Sources: MRB, internal estimates

BACK UP SLIDES

Endocrinology

A unique focus on pituitary disorders and hormone dependent diseases



A strong franchise

- A range of products addressing today Short Stature, Acromegaly and NET
  - High morbi-mortality
  - Debilitating pathologies
  - High unmet medical needs
- Somatuline®, NutropinAq® and Increlex® contributed to ~16 % of 2008 Group sales, ie. ~ €158 million.
- A fast growing franchise: sales doubled in the past 3 years

Somatuline® offers significant life cycle growth opportunities



Significant scope for expansion

BACK UP SLIDES

Oncology

Decapeptyl®: strong positions, and poised to grow



SOURCE: IMS – YTD June 2008 except for Italy: internal data

100 indicates most mature markets

Decapeptyl® 6 month formulation: a more differentiated product profile

Efficacy

- Comparable efficacy to 1 and 3 months formulation
  - **Castration levels (testosterone)**
  - **Disease control (PSA)**

Local Tolerance

- Limited local side effects (6.7% of patients)

Storage and reconstitution

- Storage at room temperature (no need to heat up before reconstitution)
- 5 Steps to reconstitute, change needle, and inject - IM route

Formulation/ Efficacy

6 month competitor 1	6 month competitor 2
80% of patients castrated after 6M [2] Testosterone to be tested every 6M* [1] Formation of Nodules or abscess [1]	Slow release formulation dependent on manual 60 mixture[1] step Storage at 2-4°: need to heat up for reconstitution [1]

Reference 1: French SmPC

[2]Avis de la commission de transparence

BACK UP SLIDES

Neurology

IPSEN
Innovation for patient care

A good track record at catching-up market shares…

Market share in medical indications



Russia
Botox launched in '94, now 56% market share
Dysport®:
Launched 5 years later, now 44% market share

South Korea
Botox launched in '95, now has 40% market share
Dysport®:
Launched 4 years later, now 23% market share

Brazil
Botox launched in '90, now has 40% market share
Dysport®:
Launched 10 years later, now 51% market share

Sources: Ipsen market intelligence

IPSEN
Innovation for patient care

An increasingly transactional model

ENDOCRINOLOGY: Roche, Genentech IN BUSINESS FOR LIFE, RADIUS, CELERA an Applera Corporation Business, Erasmus MC, rhythm

ONCOLOGY: Spirogen, Sterix, Inserm Institut national de la santé et de la recherche médicale, JOHNS HOPKINS MEDICINE, GTx The Men's Health Biotech Company, BIOMÉRIEUX, SALK INSTITUTE FOR BIOLOGICAL STUDIES, DEBIOPHARM GROUP

NEUROLOGY: cea, MEDICIS, GALDERMA Committed to the future of dermatology, Vernalis

PRIMARY CARE: TEIJIN, RECORDATI, GILEAD, Pfizer, MSD, Ginkor, Braintree

2003 - 2005 | 2006- 2009